(Q34580540)

3 August 2017

title

Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid (English)

1 reference

3 August 2017

0 references

0 references

Richard A Campbell

1

1 reference

3 August 2017

Eric Sanchez

2

1 reference

3 August 2017

Jeffrey A Steinberg

3

1 reference

3 August 2017

Stavroula Baritaki

4

1 reference

3 August 2017

Melinda Gordon

5

1 reference

3 August 2017

Cathy Wang

6

1 reference

3 August 2017

Dror Shalitin

7

1 reference

3 August 2017

Haiming Chen

8

1 reference

3 August 2017

Shen Pang

9

1 reference

3 August 2017

Benjamin Bonavida

10

1 reference

3 August 2017

Jonathan Said

11

1 reference

3 August 2017

James R Berenson

12

1 reference

3 August 2017

language of work or name

English

0 references

publication date

22 June 2007

1 reference

British Journal of Haematology

3 August 2017

published in

1 reference

3 August 2017

volume

138

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

467-478

1 reference

Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Proteasome inhibitor therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Antitumor effect of arsenic trioxide in murine xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Requirement for GSH in recycling of ascorbic acid in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Clinical activity of arsenic trioxide for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06675.X

10.1111/J.1365-2141.2007.06675.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference